Polyvalent Immunoglobulin for Intravenous Use Interferes with Cell Proliferation in Vitro

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 1992 Sep 1

PMID 1430102

Citations 18

Authors

I N van Schaik

I Lundkvist

M Vermeulen

A Brand

Affiliations

Soon will be listed here.

Abstract

Intravenous immunoglobulin is used to an increasing extent in various immune-mediated diseases, but its mechanism(s) of action in vivo is incompletely understood. Previous studies have shown that intravenous immunoglobulin may interfere with autoantibodies and their production by B cells and also inhibit Fc-mediated antibody-dependent cytotoxicity. Here we describe a novel effect of intravenous immunoglobulin on proliferation of in vitro activated peripheral blood lymphocytes and autonomously growing cell lines of various origin. Independently of whether proliferation was autonomous or induced by antigen-specific or antigen-nonspecific reagents, proliferation was inhibited in a dose-dependent fashion, as measured by reduced 3H-thymidine and BrdU uptake and cell counting. The effect was not due to cytotoxic effects of intravenous immunoglobulin and was reversible after removing the intravenous immunoglobulin by washing. The IgG levels required for this inhibition of proliferation are supraphysiological but are reached in vivo during treatment with intravenous immunoglobulin.

Citing Articles

Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis.

Ravindranath M, Hilali F, Amato-Menker C, El Hilali H, Selvan S, Filippone E Antibodies (Basel). 2022; 11(3).

PMID: 36134954 PMC: 9495617. DOI: 10.3390/antib11030058.

Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.

Ravindranath M, Hilali F, Filippone E Vaccines (Basel). 2021; 9(6).

PMID: 34205517 PMC: 8235337. DOI: 10.3390/vaccines9060680.

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency.

Dinh T, Oh J, Cameron D, Lee S, Cowan J PLoS One. 2019; 14(10):e0223861.

PMID: 31613907 PMC: 6793872. DOI: 10.1371/journal.pone.0223861.

The novel polyclonal Ab preparation trimodulin attenuates endotoxin-induced immune reactions in early hyperinflammation.

Duerr C, Bacher A, de Martin A, Sachet M, Sadeghi K, Baumann S Innate Immun. 2019; 25(6):374-388.

PMID: 31165655 PMC: 7103611. DOI: 10.1177/1753425919853333.

Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.

Li S, Jin T, Zhang H, Yu H, Meng F, Quezada H Mediators Inflamm. 2014; 2014:740947.

PMID: 24899787 PMC: 4036596. DOI: 10.1155/2014/740947.

References

Brand A, Witvliet M, Claas F, EERNISSE J . Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies. Br J Haematol. 1988; 69(4):507-11. DOI: 10.1111/j.1365-2141.1988.tb02407.x. View

Hodge J, WUST C, Ichiki A, Lozzio C . Antibodies to specific cell surface antigens of a human leukemia cell line, K-562, transduce negative growth signals. Ann N Y Acad Sci. 1991; 628:165-8. DOI: 10.1111/j.1749-6632.1991.tb17236.x. View

Fehr J, Hofmann V, Kappeler U . Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982; 306(21):1254-8. DOI: 10.1056/NEJM198205273062102. View

Delfraissy J, Tchernia G, Laurian Y, Wallon C, Galanaud P, Dormont J . Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985; 60(2):315-22. DOI: 10.1111/j.1365-2141.1985.tb07417.x. View

Jungi T, Santer M, Lerch P, BARANDUN S . Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang. 1986; 51(1):18-26. DOI: 10.1111/j.1423-0410.1986.tb00203.x. View

Leung D, Burns J, Newburger J, Geha R . Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987; 79(2):468-72. PMC: 424104. DOI: 10.1172/JCI112835. View

Buckley R, Schiff R . The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991; 325(2):110-7. DOI: 10.1056/NEJM199107113250207. View

Engelhard D, Waner J, Kapoor N, GOOD R . Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr. 1986; 108(1):77-81. DOI: 10.1016/s0022-3476(86)80772-7. View

Sultan Y, Rossi F, Kazatchkine M . Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A. 1987; 84(3):828-31. PMC: 304309. DOI: 10.1073/pnas.84.3.828. View

10.

Jayne D, Davies M, Fox C, Black C, Lockwood C . Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991; 337(8750):1137-9. DOI: 10.1016/0140-6736(91)92797-6. View

11.

Berkman S, Lee M, Gale R . Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990; 112(4):278-92. DOI: 10.7326/0003-4819-112-4-278. View

12.

van Doorn P, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine M . On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1990; 29(1-3):57-64. DOI: 10.1016/0165-5728(90)90147-f. View

13.

McGuire W, Yang H, Bruno E, Brandt J, Briddell R, Coates T . Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med. 1987; 317(16):1004-8. DOI: 10.1056/NEJM198710153171606. View

14.

Kurlander R . Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest. 1980; 66(4):773-81. PMC: 371652. DOI: 10.1172/JCI109915. View

15.

Shapiro R, CHAUVENET A, McGuire W, Pearson A, Craft A, McGlave P . Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med. 1988; 318(20):1334. DOI: 10.1056/NEJM198805193182013. View

16.

Sullivan K, Kopecky K, Jocom J, Fisher L, Buckner C, Meyers J . Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990; 323(11):705-12. DOI: 10.1056/NEJM199009133231103. View

17.

Tsubakio T, Kurata Y, Katagiri S, Kanakura Y, Tamaki T, Kuyama J . Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983; 53(3):697-702. PMC: 1535632. View

18.

Akerstrom B, Brodin T, Reis K, Bjorck L . Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. J Immunol. 1985; 135(4):2589-92. View

19.

Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine M . A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun. 1990; 3(5):547-57. DOI: 10.1016/s0896-8411(05)80020-4. View

20.

Imbach P, BARANDUN S, DApuzzo V, Baumgartner C, Hirt A, Morell A . High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 1(8232):1228-31. DOI: 10.1016/s0140-6736(81)92400-4. View